Editas Medicine
Develops an in vivo CRISPR candidate for lowering LDL cholesterol.
Something off on this page? Send us feedback.
Profile
Develops CRISPR-Cas9 medicines that edit genes directly inside the body, having pivoted in December 2024 from a discontinued sickle cell program to an in vivo pipeline led by an LDL-cholesterol candidate. Near-term revenue comes from licensing and collaboration payments tied to Vertex Pharmaceuticals and Bristol Myers Squibb rather than marketed products.
Grew out of CRISPR-Cas9 research at the Broad Institute, Harvard, and UC Berkeley, incorporated in 2013 as a clinical-stage biotechnology company developing genome-editing medicines.
An ex vivo cell therapy for sickle cell disease and thalassemia was discontinued in December 2024 alongside a roughly two-thirds workforce cut, resetting the business around in vivo editing delivered directly inside the body.
The lead candidate, EDIT-401, edits liver cells to lower LDL cholesterol, alongside an earlier-stage sickle cell program and a lipid-nanoparticle delivery platform aimed at additional tissues. Near-term revenue is non-dilutive, from a Vertex Pharmaceuticals license tied to the approved therapy CASGEVY and a Bristol Myers Squibb/Juno T-cell collaboration, with no marketed products yet.
Advancing the in vivo pipeline from preclinical work toward clinical trials depends on continued access to capital markets and on sustained Vertex and Bristol Myers Squibb payments.
Company facts
Key statistics
Year to date +53.7% · Average volume (30d) 2.2M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 5, 2026 | Chardan Capital | Reiterate | Buy | $35 | $4 | |
| Mar 10, 2026 | Jones Trading | Upgrade | Hold | Buy | ||
| Mar 9, 2026 | Robert W. Baird | Target | $10 | $6 | ||
| Dec 16, 2024 | JP Morgan | Downgrade | Neutral | Underweight | ||
| Dec 13, 2024 | Chardan Capital | Downgrade | Buy | Neutral |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.27 | −$0.15 | +44.5% | $2.8M | $11.9M | +317.7% | +5.45% |
| May 5, 2026Q1 FY26 | −$0.30 | −$0.26 | +13.3% | $6.4M | $2.8M | −55.6% | +4.61% |
| Mar 9, 2026Q4 FY25 | −$0.27 | −$0.06 | +77.8% | $8.3M | $24.7M | +196.3% | +13.79% |
| Nov 10, 2025Q3 FY25 | −$0.38 | −$0.28 | +26.3% | $8.5M | $7.5M | −10.8% | +5.56% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.7M | $3.6M | $7.5M | $24.7M | $2.8M | $11.9M | |
| Gross profit | −$21.9M | −$12.6M | −$12.2M | $24.7M | $2.3M | $11.9M | |
| Operating income | −$76.2M | −$51.5M | −$24.5M | −$14.0M | −$25.0M | −$18.6M | |
| Net income | −$76.1M | −$53.2M | −$25.1M | −$5.6M | −$25.0M | −$18.2M | |
| Diluted EPS | −$0.92 | −$0.63 | −$0.28 | −$0.06 | −$0.26 | −$0.15 | |
| Gross margin | -470.9% | -352.2% | -162.2% | 100.0% | 82.9% | 100.0% | |
| Operating margin | -1,635.1% | -1,440.6% | -325.4% | -56.7% | -883.2% | -156.0% |
Fiscal years (4-quarter sums)FY21 $25.5M · FY22 $19.7M · FY23 $78.1M · FY24 $32.3M · FY25 $40.5M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $211.6M · Total debt $15.5M · Total assets $237.4M · Shareholders' equity $105.3M
Dividends
No dividends on record.
Ownership
Shares outstanding 153.46M · Float 141.95M · 92.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 11.11M | 7.24% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 10.59M | 6.90% | 13F | Aug 7, 2026 |
| Commodore Capital LP | 8.89M | 5.79% | 13F | Aug 14, 2026 |
| Ra Capital Management, L.P. | 8.89M | 5.79% | 13F | Aug 14, 2026 |
| ADAR1 Capital Management, LLC | 8.89M | 5.80% | 13G | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | Amy Parison | officer: SVP, Chief Financial Officer | −678 | $2.58 |
| Jul 28, 2026 | Linda Burkly | officer: EVP, CHIEF SCIENTIFIC OFFICER | −4,928 | $2.67 |
| Jun 3, 2026 | Linda Burkly | officer: EVP, CHIEF SCIENTIFIC OFFICER | −731 | $2.70 |
| Jun 3, 2026 | Gilmore Neil O'Neill | director, officer: CEO | −15,380 | $2.70 |
| Jun 3, 2026 | Amy Parison | officer: SVP, Chief Financial Officer | −464 | $2.70 |
Peers
- CRISPR Therapeutics
Co-owns approved CASGEVY and builds an in vivo cardiometabolic pipeline
- Intellia Therapeutics
Runs Phase 3 in vivo CRISPR liver programs nearing first FDA approval
- Beam Therapeutics
Races in vivo liver base editing and an ex vivo sickle cell cure
- Eli Lilly
Owns an acquired in vivo PCSK9 base-editing rival for LDL-C lowering
- Prime Medicine
Prime-editing biotech pivoting to Wilson's disease and AATD liver programs
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Editas Medicine | $3.14 | −0.30% | $484.9M | — | — | 10.3 | +232.3% |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Beam Therapeutics | $29.32 | +0.10% | $3.02B | — | — | 19.3 | −94.2% |
| Eli Lilly | $1,173.00 | −0.08% | $1.10T | 39.4 | 28.7 | 13.9 | +47.7% |
| Prime Medicine | $3.59 | −0.61% | $652.0M | — | — | 160.1 | +3.5% |
| Median | 39.4 | 28.7 | 30.2 | +3.5% |